Key points are not available for this paper at this time.
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients.
Share your take
Add a clinician perspective alongside expert commentary.
Han et al. (Thu,) studied this question.